Efficacy and safety of once‐monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo‐controlled, 16‐week randomized dose‐finding study

AIMS: To determine the optimal dose(s) of once‐monthly administration of efpeglenatide, a long‐acting glucagon‐like peptide‐1 receptor agonist (GLP‐1RA), in patients with type 2 diabetes (T2D) inadequately controlled on metformin. MATERIALS AND METHODS: In this phase 2, randomized, placebo‐controlle...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Prato, Stefano, Kang, Jahoon, Trautmann, Michael E., Stewart, John, Sorli, Christopher H., Derwahl, Michael, Soto, Alfonso, Yoon, Kun‐Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383886/
https://www.ncbi.nlm.nih.gov/pubmed/32128957
http://dx.doi.org/10.1111/dom.14020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383886/
https://www.ncbi.nlm.nih.gov/pubmed/32128957
http://dx.doi.org/10.1111/dom.14020

Ejemplares similares